| ★ |  Retatrutide Cuts Weight, Cardiovascular Disease Risk in TRIUMPH-3 | | 158 | Estados Unidos | |
| 11 |  New Weight Loss Drug Retatrutide Delivers Stunning Results | | 132.4K | — | 89 |
| 7 |  Retatrutide Just Broke Every Obesity Record | Dr Brad Stanfield @drbradstanfield | 57.0K | Nueva Zelanda | 90 |
| 19 |  GLP-1s and Cardiovascular Risk: What the Latest Evidence Reveals | Metabolic Mind @metabolicmind | 49.3K | Estados Unidos | 89 |
| 9 |  Retatrutide The NEW Weight Loss Drug That SHOCKS Doctors! #retatrutide #doctor #glp1medications | Dr. G's Lifestyle Medicine Network @gooddrg | 4.2K | Estados Unidos | 90 |
| 12 |  Retatrutide Why It's a Weight Loss Game Changer! #doctor #retatrutide #dothingsyoudontwanttodo | Dr. G's Lifestyle Medicine Network @gooddrg | 3.9K | Estados Unidos | 89 |
| 6 |  Unlocking Weight Loss Secrets No Plateaus, Diabetes Reversed! #weightloss #retatrutide #glp1 | Dr. G's Lifestyle Medicine Network @gooddrg | 2.8K | Estados Unidos | 90 |
| 3 |  Retatrutide Provides Substantial Weight Loss in Patients With Obesity or Overweight | | 1.1K | Estados Unidos | 97 |
| 15 |  Retatrutide Why It's a Weight Loss Game Changer! #doctor #glp1 #retatrutide #lifestylemedicine | Dr. G's Lifestyle Medicine Network @gooddrg | 1.1K | Estados Unidos | 89 |
| 10 |  Retatrutide (The Next Generation GLP 1 Drug) | Dr. Marc Morris @drmarcmorris | 958 | Canadá | 90 |
| 16 |  Retatrutide: The GLP-3 Drug Revolutionizing Weight Loss & Metabolism! | | 587 | Estados Unidos | 89 |
| 1 |  Diabetes Dialogue: Retatrutide Phase 3 Data Show Major Weight Loss | | 533 | Estados Unidos | 98 |
| 2 |  TRIUMPH-2: Retatrutide Reduces Weight, A1C in Patients With Obesity | | 350 | Estados Unidos | 97 |
| 17 |  Diabetes Dialogue: Weekly Insulin Icodec Now Available for Type 2 Diabetes | | 206 | Estados Unidos | 89 |
| 14 |  Diabetes Dialogue: CKM Systems, Triple Agonists, and a Sensor Scandal Ahead of ADA | | 179 | Estados Unidos | 89 |
| 20 |  SYNCHRONIZE-1: Survodutide Achieves Significant Weight Loss Versus Placebo | | 174 | Estados Unidos | 89 |
| 8 |  Rapid Evolution in GLP-1s and Therapeutics at ADA 2026 | | 171 | Estados Unidos | 90 |
| 4 |  Diabetes Dialogue: CONNECT, TRANSCEND, and TRIUMPH at ADA 2026 | | 114 | Estados Unidos | 91 |
| 5 |  Incretins, Monitors, and Insulin Titration at ADA 2026 | | 76 | Estados Unidos | 90 |
| 13 |  Diabetes Dialogue: Signos and the Science of Weight Loss | | 75 | Estados Unidos | 89 |
| 18 |  Continuous Ketone Monitoring May Guide SGLT2i Use in T1D | | 33 | Estados Unidos | 89 |